Compare Grab Holdings Ltd. (GRAB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs IDEXX Laboratories, Inc. — how do they compare? Grab Holdings Ltd. trades at $3.61 (market cap $15.26B), while IDEXX Laboratories, Inc. trades at $573.33 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× Grab Holdings Ltd.'s market cap. Which is the better fit depends on your goals.
| GRAB | IDXX | |
|---|---|---|
Market Cap | $15.26B | $46.22B |
Sector | Technology | Health |
52-Week High | $6.45 | $766.68 |
52-Week Low | $3.27 | $526.44 |
Enterprise Value | $10.99B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.605, down 1.77% today, but maintains a bullish technical trend. The company reported strong Q2 2026 earnings, beating estimates with $0.06 EPS, and raised full-year revenue guidance to 22-23% growth. Positive analyst sentiment includes an average price target of $5.86, implying 58% upside. Fundamentals show improving profitability, with net income turning positive in 2025 at $268 million and margins expanding.
Outlook is positive given earnings momentum and raised guidance, but risks include high valuation multiples, insider selling, and competitive pressures in Southeast Asia. The stock offers growth potential if execution continues, yet investors should weigh valuation against profitability sustainability and market volatility.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
